Cancer vaccine - Acuvax

Drug Profile

Cancer vaccine - Acuvax

Alternative Names: p53 cancer vaccine - Avantogen; Pentrix; Pentrys; Pentrys prostate vaccine - Avantogen; Prostate cancer vaccine - Avantogen

Latest Information Update: 02 Sep 2015

Price : $50

At a glance

  • Originator Avantogen
  • Developer Acuvax
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 28 Apr 2006 This vaccine is still in active development
  • 30 May 2005 Australian Cancer Technology is now called Avantogen
  • 23 Mar 2005 Australian Cancer Technology has completed enrolment in a phase IIb trial for hormone-refractory prostate cancer in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top